Novartis reports positive results from Cosentyx trial
Novartis has reported that data from two pivotal Phase III trials of Cosentyx (secukinumab) demonstrated fast and strong skin clearance…
Latest News
-
5 hours
-
23 hours
-
1 day
-
1 day
-
5 hours
-
23 hours
-
1 day
-
1 day
Lilly reports positive data from multiple psoriasis trials
Eli Lilly and Company has reported that multiple long-term and post-hoc analyses of the monoclonal antibody Taltz (ixekizumab) showed sustained…
Latest News
View More
Boehringer initiates trial of targeted therapy to treat Covid-19 patients
Boehringer Ingelheim has initiated a Phase II clinical trial of a novel compound, BI 764198, for treating hospitalised Covid-19 patients with acute respiratory complications. BI…
Aurinia initiates voclosporin trial in KTRs with Covid-19
Aurinia Pharmaceuticals has initiated an open-label exploratory trial to analyse the antiviral effects of voclosporin in kidney transplant recipients (KTRs) with Covid-19. Aurinia also secured…
Prilenia begins patient enrolment in HD drug trial in US
Prilenia Therapeutics has enrolled the first patients in a Phase III trial of pridopidine for the treatment of Huntington’s Disease…
Olatec Therapeutics initiates enrolment in oral drug trial for Covid-19
Olatec Therapeutics has initiated patient enrolment in a Phase II trial to analyse the safety and efficacy of oral NLRP3…
HiFiBiO Therapeutics concludes first cohort of Covid-19 antibody study
HiFiBiO Therapeutics has successfully completed the first cohort of the Phase I trial (NCT04590430) of SARS-CoV-2 neutralising antibody, HFB30132A, to…
Novartis’ iptacopan reduces proteinuria in rare renal disease trial
Novartis has announced that interim analysis results from the Phase II trial of iptacopan (LNP023) showed the oral therapy significantly…
Latest Content
View More
Sanofi and Regeneron report eosinophilic esophagiti trial data
Sanofi and Regeneron Pharmaceuticals have reported additional positive results from Part A of a Phase III trial evaluating Dupixent (dupilumab)…
AstraZeneca’s Farxiga prolongs survival in chronic kidney disease trial
AstraZeneca has reported positive data from a subgroup analysis from Phase III DAPA-CKD trial of Farxiga (dapagliflozin) in patients with…
WAKIX (pitolisant) for the Treatment of Cataplexy with Narcolepsy
WAKIX® (pitolisant) is the first and only non-scheduled medication indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS)…
Real Time Cargo Intelligence to Increase Distribution Quality and Security
Smooth visibility from the place of production to the ultimate destination must be the new standard for vaccine delivery. The…
SIMPONI ARIA (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis (pJIA)
SIMPONI ARIA® (golimumab) is a fully human anti-tumour necrosis factor (TNF) alpha monoclonal antibody. It is indicated for the treatment…
SOM Biotech Announces Poster Presentation on the Repurposing of Eravacycline for the Treatment of SARS-CoV-2
SOM Biotech, a biopharmaceutical company specialising in the repositioning of existing drugs for the treatment of diseases with a high…